Skip to main content

CORRECTION article

Front. Pharmacol., 06 January 2025
Sec. Renal Pharmacology
Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1548193

Corrigendum: Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation

This article is a correction to:

  1. Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation

    1. Read original article
Guangzhuang LiGuangzhuang Li1Sentao XianSentao Xian2Xianchao ChengXianchao Cheng3Yunhua HouYunhua Hou1Wenqing Jia Wenqing Jia2*Yukui Ma Yukui Ma2*
  • 1School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China
  • 2School of Chemistry and Chemical Engineering, Qilu Normal University, Jinan, China
  • 3Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China

A Corrigendum on
Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation

by Li G, Xian S, Cheng X, Hou Y, Jia W and Ma Y (2024). Front. Pharmacol. 15:1499012. doi: 10.3389/fphar.2024.1499012

In the published article, there was an error in Affiliation 1. Instead of “School of Bioengineering, Shandong Academy of Sciences, Qilu University of Technology, Jinan, China,” it should be “School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Oroxylin A, chronic kidney disease, renal fibrosis, Sirt1, molecular docking

Citation: Li G, Xian S, Cheng X, Hou Y, Jia W and Ma Y (2025) Corrigendum: Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation. Front. Pharmacol. 15:1548193. doi: 10.3389/fphar.2024.1548193

Received: 19 December 2024; Accepted: 20 December 2024;
Published: 06 January 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Li, Xian, Cheng, Hou, Jia and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wenqing Jia, d2VucWluZ2ppYTAzMTJAMTYzLmNvbQ==; Yukui Ma, eWFvbGlkdWxpQDE2My5jb20=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.